119 related articles for article (PubMed ID: 38409760)
1. 68 Ga-PSMA Uptake in the Testis : Two Different Patients With Two Different Diagnosis.
Calderon Tobar MN; Önner H
Clin Nucl Med; 2024 Jun; 49(6):578-579. PubMed ID: 38409760
[TBL] [Abstract][Full Text] [Related]
2. Clinical utility of [68Ga]Ga-PSMA-11 PET/CT in initial staging of patients with prostate cancer and importance of intraprostatic SUVmax values.
Rogic I; Golubic AT; Zuvic M; Smitran T; Jukic N; Gamulin M; Kastelan Z; Huic D
Nucl Med Rev Cent East Eur; 2024; 27(0):6-12. PubMed ID: 38680016
[TBL] [Abstract][Full Text] [Related]
3. An Unexpected Seminal Vesicle Pitfall in PSMA PET.
Bronte A; Rosales JJ; Torres Roca M; Miñana B; Rodríguez-Fraile M
Clin Nucl Med; 2024 Jun; 49(6):e274-e275. PubMed ID: 38537177
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous, Subcutaneous, and Bilateral Adrenal Gland Metastases in Progressive Prostate Carcinoma: Theranostic Potential of 68 Ga-PSMA-11 PET/CT Imaging and 177 Lu-PSMA-617 Therapy.
Parghane RV; Basu S
Clin Nucl Med; 2024 Jun; 49(6):587-588. PubMed ID: 38557426
[TBL] [Abstract][Full Text] [Related]
5. 68Ga-PSMA-11 PET/CT Follow-Up of Patients with Prostate Cancer with Bone Metastases Who Had Reduced Bone Density after Androgen Deprivation Therapy.
Kesler M; Druckmann I; Levine C; Kuten J; Yossepowitch O; Even-Sapir E
Diagnostics (Basel); 2021 Feb; 11(2):. PubMed ID: 33578990
[TBL] [Abstract][Full Text] [Related]
6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
7. 68Ga-PSMA PET/CT in prostate cancer patients - patterns of disease, benign findings and pitfalls.
Keidar Z; Gill R; Goshen E; Israel O; Davidson T; Morgulis M; Pirmisashvili N; Ben-Haim S
Cancer Imaging; 2018 Nov; 18(1):39. PubMed ID: 30382889
[TBL] [Abstract][Full Text] [Related]
8. Atypical Presentation of Liver Metastases of Prostate Cancer in 68Ga-PSMA-11 PET/CT.
Stanzel S; Weitzer F; Janek E; Plhak E; Aigner RM
Clin Nucl Med; 2023 Dec; 48(12):1064-1065. PubMed ID: 37934704
[TBL] [Abstract][Full Text] [Related]
9. Primary lymph-node staging with
Corona-Montes VE; González-Cuenca E; Fernández-Noyola G; Olarte-Casas MA; Bobadilla-Salazar D; Medrano-Urtecho HM; Asimakopoulos AD
Urol Oncol; 2021 Aug; 39(8):494.e1-494.e6. PubMed ID: 33223371
[TBL] [Abstract][Full Text] [Related]
10. Concomitant Prostate Cancer and Hodgkin Lymphoma: A Differential Diagnosis Guided by a Combined 68Ga-PSMA-11 and 18F-FDG PET/CT Approach.
Miceli A; Riondato M; D'Amico F; Donegani MI; Piol N; Mora M; Spina B; Morbelli S; Bauckneht M
Medicina (Kaunas); 2021 Sep; 57(9):. PubMed ID: 34577898
[TBL] [Abstract][Full Text] [Related]
11. Enhancing PSMA-uptake with androgen deprivation therapy - a new way to detect prostate cancer metastases?
Leitsmann C; Thelen P; Schmid M; Meller J; Sahlmann CO; Meller B; Trojan L; Strauss A
Int Braz J Urol; 2019; 45(3):459-467. PubMed ID: 30901173
[TBL] [Abstract][Full Text] [Related]
12. 68Ga/64Cu PSMA Bio-Distribution in Prostate Cancer Patients: Potential Pitfalls for Different Tracers.
Calabria F; Pichler R; Leporace M; Wolfsgruber J; Coscarelli P; Dunzinger A; Schillaci O; Cascini GL; Bagnato A
Curr Radiopharm; 2019; 12(3):238-246. PubMed ID: 31113354
[TBL] [Abstract][Full Text] [Related]
13. The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature.
Eissa A; Elsherbiny A; Coelho RF; Rassweiler J; Davis JW; Porpiglia F; Patel VR; Prandini N; Micali S; Sighinolfi MC; Puliatti S; Rocco B; Bianchi G
Minerva Urol Nefrol; 2018 Oct; 70(5):462-478. PubMed ID: 29664244
[TBL] [Abstract][Full Text] [Related]
14. Lymph node staging with 68Ga-PSMA PET in patients with intermediate and high-risk prostate cancer suitable for radical prostatectomy managed in a prostate cancer unit.
Maestroni UV; Campobasso D; Guarino G; Acampora A; Scarlattei M; Ziglioli F; Dinale F; Baldari G; Migliari S; Gasparro D; Ferretti S; Silini EM; Ruffini L
Chin Clin Oncol; 2023 Jun; 12(3):22. PubMed ID: 37417288
[TBL] [Abstract][Full Text] [Related]
15. Detection of metastases in newly diagnosed prostate cancer by using 68Ga-PSMA PET/CT and its relationship with modified D'Amico risk classification.
Simsek DH; Sanli Y; Engin MN; Erdem S; Sanli O
Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1639-1649. PubMed ID: 32789600
[TBL] [Abstract][Full Text] [Related]
16. Could 68Ga-PSMA PET/CT Evaluation Reduce the Number of Scheduled Prostate Biopsies in Men Enrolled in Active Surveillance Protocols?
Pepe P; Roscigno M; Pepe L; Panella P; Tamburo M; Marletta G; Savoca F; Candiano G; Cosentino S; Ippolito M; Tsirgiotis A; Pennisi M
J Clin Med; 2022 Jun; 11(12):. PubMed ID: 35743547
[TBL] [Abstract][Full Text] [Related]
17. 68Ga-PSMA PET/CT: Does it predict adverse pathology findings at radical prostatectomy?
Dekalo S; Kuten J; Mabjeesh NJ; Beri A; Even-Sapir E; Yossepowitch O
Urol Oncol; 2019 Sep; 37(9):574.e19-574.e24. PubMed ID: 31204017
[TBL] [Abstract][Full Text] [Related]
18. Role of 68Ga-PSMA-PET/CT for the detection of primary prostate cancer prior to biopsy: a prospective study.
Jain H; Sood R; Faridi MS; Goel H; Sharma U
Cent European J Urol; 2021; 74(3):315-320. PubMed ID: 34729219
[TBL] [Abstract][Full Text] [Related]
19. 68Ga-PSMA-11 PET/CT in a Case of Isolated Parietal Peritoneal Metastasis From Prostate Adenocarcinoma.
Zhao Q; Dong A; Zuo C
Clin Nucl Med; 2023 Oct; 48(10):913-914. PubMed ID: 37682611
[TBL] [Abstract][Full Text] [Related]
20. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
